Determining whether your prostate cancer patients are safe for active surveillance or would benefit from single- or multimodal treatment can be challenging. Traditional risk assessment methods may not provide the full picture, leading to uncertainty in treatment decisions.
Introducing Prolaris®, a prostate cancer prognostic test that combines traditional prognostic factors with an individualized molecular score to stratify patient risk precisely. It adds significant prognostic power to traditional prostate cancer risk assessment methods1, providing you with the confidence to develop the right treatment plan.
Prolaris® provides precise risk stratification by combining PSA & Gleason with an independent gene expression score based on cell cycle proliferation (CCP).
Prolaris® is the only test with validated thresholds for active surveillance2 and multimodal treatment in untreated patients3,4. Assess risk for any patient in any NCCN risk group.2
Prolaris® helps you safely prescribe active surveillance or single and multimodal therapy for men who need it, empowering your treatment decisions.
With the prognostic power of Prolaris®, trusted by over 5 million patients worldwide, we bring clarity to your prostate cancer treatment decisions. As recommended by national cancer guidelines, Prolaris® provides the confidence needed to navigate treatment decisions effectively.
1. Prescribe Prolaris®
Prolaris® utilizes existing tissue from the diagnostic biopsy. No additional biopsies or blood draws are required. All you need to do is prescribe.
2. Let the lab do the work
Once prescribed, the lab takes over. Using advanced technology, the lab analyzes the biopsy sample to generate a Prolaris® Score.
3. Use the Power of the Result
With the patient’s 10-year disease-specific mortality or metastasis risk, make personalized treatment decisions under conservative or curative interventions.
The Prolaris® white paper tells the story of consistent data across its range of clinical validation and utility studies.
Request the white paper to learn how it can provide life-changing insights for your patients.
Upon prescribing Prolaris®, you unlock a powerful tool in personalized prostate cancer treatment.
The lab analyzes the biopsy sample, generating a Prolaris Score that estimates your patient’s 10-year prostate cancer mortality or metastasis risk according to a conservative or curative approach. This score, visualized on a graph, provides a clear understanding of the patient’s unique risk profile.
With this knowledge, you can confidently make personalized treatment decisions. This process, trusted by over 5 million patients and recommended by national cancer guidelines, brings precision and confidence to your clinical practice.
It’s not just about treating prostate cancer – it’s about treating your patient in the best way for them.